Chronic Heart Failure: PBAC Recommends Empaglif...

By Staff Writer

April 14, 2023

Introduction: The Pharmaceutical Benefits Scheme (PBS) included Empagliflozin, a sodium glucose co transporter 2 (SGLT2) inhibitor, for chronic heart failure (CHF) treatment with reduced ejection fraction ...
Genedrive MT-RNR1 ID Kit to detect genetic variation and protect hearing in b...
Abu Dhabi Recognises Abu Dhabi Stem Cells Center (ADSCC) as a Centre of Excel...
Did CVDs recover post COVID-19 ?
The evidence for Cannabidiol is building
Mobocertinib added in NICE guidelines
HIQA on Gene Expression Profiling Tests for Breast Cancer
Upadacitinib: A Convenient and Effective Alternative Treatment for Spondyloar...
SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment